Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries

被引:130
作者
Sabeti, S [1 ]
Mlekusch, W [1 ]
Amighi, J [1 ]
Minar, E [1 ]
Schillinger, M [1 ]
机构
[1] Univ Vienna, Sch Med, Dept Angiol, Vienna, Austria
关键词
femoropopliteal segment; stenosis; angioplasty; nitinol stent; restenosis;
D O I
10.1583/04-1359.1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: To report a retrospective cohort study of nitinol stent implantation in patients at high risk for restenosis owing to long-segment (greater than or equal to10 cm) femoropopliteal disease. Methods: Sixty-five consecutive patients with peripheral artery disease underwent long-segment (greater than or equal to10 cm) femoropopliteal stent implantation using self-expanding nitinol stents after initial failure of plain balloon angioplasty (i.e., residual stenosis >30% or a flow-limiting dissection). Patients were followed for first occurrence of in-stent restenosis, defined as a >50% lumen diameter reduction by color-coded duplex sonography, with angiographic confirmation. Results: Cumulative median length of the stented segments was 16 cm (interquartile range [IQR] 12-25, absolute range 10-40) using up to 5 overlapping stents. During the median 8-month follow-up (lQR 6-11), no early thrombotic reocclusions occurred within 30 days, but 26 (40%) patients developed an in-stent restenosis. Cumulative freedom from restenosis at 6 and 12 months was 79% and 54% overall, respectively; at the same time periods, the rates were 84% and 71% in nondiabetic patients (n=41) versus 68% and 22% in diabetics (n=24) (adjusted hazard ratio 3.8, p=0.01). Cumulative stent length and number of implanted stents were not associated with restenosis. Conclusion: Midterm restenosis after long-segment femoropopliteal stenting using self-expanding nitinol stents remains a major problem, particularly in patients with diabetes mellitus. The midterm results in nondiabetics are encouraging.
引用
收藏
页码:6 / 12
页数:7
相关论文
共 21 条
[1]   Clinical results for the training-phase roll-in patients in the IntraCoil femoralpopliteal stent trial [J].
Ansel, GM ;
Botti, CF ;
George, BS ;
Kazienko, BT .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 56 (04) :443-449
[2]  
CAPEK P, 1991, CIRCULATION, V83, P70
[3]   PTA versus Palmaz stent placement in femoropopliteal artery obstructions: A multicenter prospective randomized study [J].
Cejna, M ;
Thurnher, S ;
Illiasch, H ;
Horvath, W ;
Waldenberger, P ;
Hornik, K ;
Lammer, J .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2001, 12 (01) :23-31
[4]   Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease [J].
Duda, SH ;
Pusich, B ;
Richter, G ;
Landwehr, P ;
Oliva, VL ;
Tielbeek, A ;
Wiesinger, B ;
Hak, JB ;
Tielemans, H ;
Ziemer, G ;
Cristea, E ;
Lansky, A ;
Bérégi, JP .
CIRCULATION, 2002, 106 (12) :1505-1509
[5]   High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty [J].
Gray, BH ;
Sullivan, TM ;
Childs, MB ;
Young, JR ;
Olin, JW .
JOURNAL OF VASCULAR SURGERY, 1997, 25 (01) :74-83
[6]   Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions [J].
Grimm, J ;
Müller-Hülsbeck, S ;
Jahnke, T ;
Hilbert, C ;
Brossmann, J ;
Heller, M .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2001, 12 (08) :935-941
[7]  
Henry M, 1996, J ENDOVASC SURG, V3, P369, DOI 10.1583/1074-6218(1996)003<0369:CEWANN>2.0.CO
[8]  
2
[9]  
Henry M, 2003, J ENDOVASC THER, V10, P772, DOI 10.1583/1545-1550(2003)010<0772:CEWTOS>2.0.CO
[10]  
2